Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Platform Study of HR+/HER2- Advanced Breast Cancer (SNF Typing)
NCT05594095Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, tizetatug rezetecan, ruzaltatug rezetecan, SHR-A2102, M9466 in Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+), sponsored by Fudan University. Started Dec 2022; status: recruiting.
02
Drugs
trastuzumab rezetecantizetatug rezetecanruzaltatug rezetecanSHR-A2102M9466
03
Conditions
Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+)
Beyond the preview
Go deeper on NCT05594095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594095.